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Abstract objective To compare socio-demographic patterns in access to antiretroviral therapy (ART) across
four community HIV cohort studies in Africa.
methods Data on voluntary counselling and testing and ART use among HIV-infected persons were
analysed from Karonga (Malawi), Kisesa (Tanzania), Masaka (Uganda) and Manicaland (Zimbabwe),
where free ART provision started between 2004 and 2007. ART coverage was compared across sites by
calculating the proportion on ART among those estimated to need treatment, by age, sex and educa-
tional attainment. Logistic regression was used to identify socio-demographic characteristics associated
with undergoing eligibility screening at an ART clinic within 2 years of being diagnosed with HIV, for
three sites with information on diagnosis and screening dates.
results Among adults known to be HIV-infected from serological surveys, the proportion who knew
their HIV status was 93% in Karonga, 37% in Kisesa, 46% in Masaka and 25% in Manicaland.
Estimated ART coverage was highest in Masaka (68%) and lowest in Kisesa (2%). The proportion of
HIV-diagnosed persons who were screened for ART eligibility within 2 years of diagnosis ranged from
14% in Kisesa to 84% in Masaka, with the probability of screening uptake increasing with age at
diagnosis in all sites.
conclusions Higher HIV testing rates among HIV-infected persons in the community do not neces-
sarily correspond with higher uptake of ART, nor more equitable treatment coverage among those in
need of treatment. In all sites, young adults tend to be disadvantaged in terms of accessing and initiating
ART, even after accounting for their less urgent need.
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Introduction
Various approaches have been taken to scaling up HIV
testing and treatment services in sub-Saharan Africa,
depending on human resource availability, funding mech-
anisms, national policy and health infrastructure. In
particular, alternative models to traditional voluntary
counselling and testing (VCT) services, including mobile,
door-to-door or workplace VCT services, and opt-out HIV
testing in health facilities, are increasingly being promoted
to improve low HIV diagnosis rates (Matovu & Makumbi
2007; WHO 2008). While these strategies can increase the
number of persons who learn their status (Menzies et al.
2009), they may also increase the proportion of HIV-
infected persons who know their positive status but fail to
enrol in HIV treatment programmes.
A recent systematic review of pre-antiretroviral therapy
(ART) retention in care in Africa showed that the median
rate of attrition between receiving a HIV diagnosis and
subsequently enrolling at a HIV treatment clinic was 41%
(range: 12–65%), while the median attrition rate from
staging to ART eligibility was 54% (5–69%) and from
ART eligibility to treatment initiation was 32% (16–86%)
(Rosen & Fox 2011). However, none of the included
studies provided a complete picture in terms of dropout at
every stage of the process of accessing ART – from the
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time of diagnosis right through to ART initiation – or
related these findings to estimated ART coverage in the
population. Such an analysis would require information on
the estimated proportion of HIV-infected persons who
need HIV treatment, which is itself a function of the stage
of the epidemic and the age distribution of HIV incidence
over time (Zaba et al. 2012).
Community-level HIV cohort studies provide a unique
opportunity to track progress in coverage with HIV testing
and treatment services in relation to need for treatment, as
HIV programmes are rolled out. The availability of age-
specific HIV prevalence data and mortality rates enables
estimates of ART need to be made by characteristics
including age, sex and area of residence (Zaba et al. 2012).
Data on HIV service use including HIV testing, referral
and ART clinic attendance can be anonymously linked to
data on the total community population, so that the
proportion of all HIV-infected persons who have accessed
each service can be estimated at a given point in time. Cross-
country comparisons can shed light on the extent to which
different strategies for providing HIV testing and treatment
have resulted in higher HIV testing and treatment coverage,
or greater equity in terms of ART coverage, providing
information that is important for informing current HIV
testing and treatment policies. This study compares HIV
testing and treatment uptake in four cohort studies in
Malawi, Tanzania, Zimbabwe and Uganda.
Methods
Participating sites and study settings
Four HIV cohort studies participating in the ALPHA
network contributed data for this analysis: Karonga
(Malawi), Kisesa (Tanzania), Masaka (Uganda) and Man-
icaland (Zimbabwe). Sites were selected if they collected
data on participants’ use of HIV testing services and ART
initiation, and preferably referral to HIV treatment clinics.
These data were collected either from (i) attendance
records at local HIV testing and HIV treatment clinics that
could be anonymously linked to the data collected during
the serological survey rounds or (ii) from self-reported
information collected from questionnaires administered
during the serological surveys.
Table 1 summarises the data sources used and the dates
that HIV services were introduced for each site in the
analysis. A description of the study setting, data collection
methods and HIV service availability for each site is also
provided below. More detailed descriptions for each study
setting and the construction of each dataset are provided in
previous publications (Cremin et al. 2009; Floyd et al.
2010) and in site-specific analyses of VCT and ART uptake
that are presented elsewhere in this supplement (Kazooba
et al. 2012).
Karonga
Karonga district is a rural area in northern Malawi, where
demographic surveillance surveys (DSS) have been con-
ducted among a sub-population of 33 500 individuals since
2002–2004, collecting monthly information on births and
deaths, and migration information each year. Serological
surveillance has been conducted annually since September
2007 among all individuals aged 15 years or over residing
in the DSS area. HIV testing, with pre- and post-test
counselling, is offered at participants’ homes, using rapid
tests, with referrals made to the nearest ART clinic for
those with an HIV-positive diagnosis. In addition, a
detailed questionnaire is administered covering prior VCT
use, referral to HIV clinics and ART use.
Antiretroviral therapy was first available to the study
population at a district clinic in June 2005. By the time of
the first serological surveillance round, additional health
facilities were providing ART, including one within the
DSS area. Data from patient records at the ART clinic in
the DSS area have been anonymously linked to cohort
records since January 2008.
Kisesa
The Kisesa cohort study comprises five rural villages and a
trading centre in north-west Tanzania. Serological surveys
are conducted every 3 years, with demographic surveil-
lance carried out separately during biannual household
visits among approximately 29 000 individuals (Mwaluko
et al. 2003). During serological surveys, HIV testing was
conducted for research purposes without results disclosure
among consenting adults, and a detailed questionnaire was
administered covering health service use and sexual
behaviour.
Since the 2003–2004 serological survey, separate, tem-
porary VCT services were offered to participants in each
village. In addition, a government-run VCT clinic was
available at the local health centre within the surveillance
area since 2005, with free ART available at a referral
hospital 20 km away. Referrals to the ART clinic were
made from the survey VCT and the health centre VCT
services since the ART programme started, with data from
referral forms and the ART clinic linked to the VCT data
using numerical identifiers (Nsigaye et al. 2009). The VCT
data have been anonymously linked to the cohort data
since 2005.
Masaka
The Masaka cohort study is located in rural south-west
Uganda. An annual household survey has been conducted
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since 1989, with all residents in the study area eligible for
inclusion (Mbulaiteye et al. 2002). Demographic and
HIV surveillance data are collected during annual house-
to-house rounds. Survey participants who want to learn
their status are referred to local VCT centres, where they
are informed of their result, following counselling.
In addition, one-third of the HIV-infected adults who
participated in the first survey in 1990 were selected at
random to participate in a ‘clinical cohort’ (Morgan et al.
1997). The clinical cohort now includes all HIV serocon-
verters from subsequent rounds, together with age-
matched HIV-negative controls. Participants attend med-
ical follow-up visits at the study clinic every 3 months,
with ART provision available for eligible and consenting
participants since January 2004. The clinic also provides
HIV treatment to others living in the study area and is the
sole ART provider in the area.
Manicaland
The Manicaland cohort study in Zimbabwe is a popula-
tion-based open cohort of men and women aged 15–54 in
12 communities representing four socio-economic strata –
(i) small towns; (ii) large-scale tea, coffee and forestry
estates; (iii) roadside trading settlements; and (iv)
Table 1 Characteristics of each study site
Site Karonga Kisesa Masaka Manicaland
HIV service availability
Date of VCT introduction
(excluding serosurveys)*
2005 2005 2004 2000
First serosurvey round with VCT 2007–2008 2003–2004 1989 2000
Date of free ART introduction in
the study area
June 2005 March 2005 January 2004 January 2007
Criteria for ART initiation CD4 < 200 (250 Karonga), or WHO stage 4 ⁄ stage 3; CD4 < 250 for pregnant women
Data sources
Data source for VCT use and date Reported,
home-based
Reported, clinic Reported, clinic Reported
Data source for referral to ART
clinic and date
Reported, clinic Clinic N ⁄A N ⁄A
Data source for ART clinic
registration and date
Clinic Clinic N ⁄A N ⁄A
Data source for ART screening
and date
Clinic Clinic Clinic N ⁄A
Data source for ART eligibility
and date
Clinic Clinic Clinic (CD4 only) N ⁄A
Data source for ART initiation
and date
Reported, clinic Clinic Clinic Reported, no date
Cross-sectional analysis
Year of survey 2007–2008 2006–2007 2008 2006–2008
HIV prevalence at survey 6.3% (M), 8.5% (F) 5.1% (M), 6.7% (F) 5.9% (M), 8.9% (F) 12.5% (M), 18.8% (F)
Number of HIV+ eligible for survey 837 676 575 2057
Prospective analysis
Residence eligibility for inclusion of
HIV+, ART-naive persons in the
analysis
Resident at
2007–2008 survey;
interviewed after
January 2008
Resident at
2006–2007
survey
Resident at 2005
or 2006 survey
N ⁄A
Period of diagnosis January 2008–
October 2008
2005–2007 2004–2006 N ⁄A
Period of screening January 2008–June
2010
2005–2009 2004–2008 N ⁄A
Persons included in the analysis 473 676 636 N ⁄A
ART, antiretroviral therapy; VCT, voluntary counselling and testing.
*Since the availability of ART.
ln Manicaland, ART was introduced in the study area in 2005 with very limited availability and with scale-up occurring gradually
from 2007onwards.
Specific stage 3 conditions in Masaka, Kisesa and Manicaland.
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subsistence farming areas. Prior to each survey, eligible
participants were identified through a household census.
Detailed information on demographics, sexual behaviour
and health service use was collected through face-to-face
interviews every 2–3 years between 1998 and 2008
(Gregson et al. 2006; Cremin et al. 2009). Anonymous
HIV testing for research purposes was carried out at the
time of the interview. All participants were offered free
VCT provided by trained nurse counsellors from the
study’s mobile VCT clinic, and infected individuals were
referred to local clinics or hospitals for ART. Information
on VCT service use was collected during each survey, with
questions on ART use added in the 2003–2005 round.
Statistical methods
Two analyses were undertaken using Stata 11 (StataCorp,
College Station, TX, USA). The first, a cross-sectional
analysis, describes the distribution of the HIV-infected
adult population in each site in terms of HIV and ART
services accessed at the time of a recent serological survey.
The number of persons who had initiated ART was
compared to the total number of HIV-infected persons, and
the number estimated to be in need of treatment at the time
of the survey, using the methods described below.
The second analysis prospectively assesses the delays
between being diagnosed with HIV (defined as having a
positive HIV test and receiving the results) and subse-
quently being screened at an HIV treatment clinic. This
analysis includes the three sites (Karonga, Kisesa and
Masaka) that had information on diagnosis and screening
dates, as well as age and education level at time of
diagnosis. The time-period and number of participants in
the denominator for each of the two analyses, by site, are
shown in Table 1.
HIV service coverage: a cross-sectional analysis
For the cross-sectional analysis, each site provided data
from a recent serological surveillance round for everyone in
the DSS population who was age-eligible for the selected
serological survey. The dataset from each site included at
least HIV status, HIV testing with receipt of results,
initiation of ART, date of birth and sex. Three sites
(Karonga, Kisesa and Masaka) provided additional infor-
mation on the intermediary steps between HIV diagnosis
and ART initiation, including whether a person was
referred for HIV treatment, and ⁄or whether they had
registered at a HIV clinic and ⁄or whether they had
completed ART eligibility screening (Table 1).
Participants from Kisesa and Masaka were included in
the analysis if they were eligible to attend the selected
serological surveillance round and had tested HIV-positive
either at the selected round, or at any previous round
attended, regardless of whether the participant was aware
of their HIV status. This inclusion criterion maximised the
baseline number of HIV-infected persons in the population,
reducing the risk of under- or overestimating HIV service
coverage as a result of participation bias. Participants for
Manicaland were included if they attended the 2006–2008
survey and had tested HIV-positive either at that round
or at any previous serological surveillance round attended,
as ART use was self-reported, and could thus only be
obtained among those attending the 2006–2008 round.
Participants for Karonga were included in the analysis if
they tested HIV-positive in the 2007–2008 round, as this
was the first serological survey covering the entire DSS
population.
For each of the four participating sites, the following
proportions were calculated among HIV-infected adults
aged 15 years and older, for the available data: (i) learned
their HIV status, (ii) registered at a HIV treatment clinic,
(iii) completed ART eligibility screening; (iv) been eligible
to initiate ART and (v) initiated ART. Cross-tabulations
and bar graphs were used to compare the distribution of
the use of HIV and ART services among the HIV-infected
population, by age and sex across the four sites.
Age- and sex-specific estimates of ART coverage were
calculated for each site by comparing the estimated number
of persons in need of treatment with the number currently
on ART, for the chosen survey year. The proportion of
adults estimated to need therapy was determined using the
methods that have been described in detail by Zaba et al.
(2012) in this supplement. In brief, age-specific mortality
among all HIV-infected adults was described using a
Weibull model, fitted to mortality patterns observed in the
ALPHA network sites prior to ART availability, using
time-to-event parametric regression on age at death among
the HIV infected (Zaba et al. 2007). The regression model
can be summarised as:
survival probability in the infected state from age
15 to age A ¼ expð0:0073  ðA 15Þ1:69Þ
This fitted model life table allows the calculation of the
conditional probability of survival for infected persons
from any age for a fixed number of years in the absence
of treatment. At the start of an ART programme, the
proportion of infected individuals needing ART at each
age was estimated as their probability of dying in the
next 3 years, on the assumption that HIV-infected
individuals reach a CD4 of 200 approximately 3 years
prior to death in the absence of ART (Wandel et al. 2008).
For each subsequent year of the programme, the
estimated proportion needing ART was augmented by
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the proportion expected to die 1 year later. These
predicted probabilities were then summed together to
obtain an estimate of the proportion of HIV-infected
adults in need of ART, among those included in the
analysis.
Delays between receipt of a HIV diagnosis and ART
screening: a prospective analysis
The prospective analysis assessed the delays between a
HIV diagnosis and ART screening in three sites (Karonga,
Kisesa and Masaka) that had data on HIV diagnosis
date and ART eligibility screening date, enabling the
delay between these two events to be calculated.
Additional details on the methods for determining dates of
diagnosis and screening have been described elsewhere
(Floyd et al. 2010; Kazooba et al. 2012).
For Karonga, the analysis was restricted to HIV-infected
participants reporting that they were ART-naive and who
were interviewed after the 22 January 2008, to ensure that
screening rates were not underestimated because data on
ART screening from the local ART clinic were only
available from the end of January 2008 up to mid-2010.
Participants from Kisesa were included in the analysis if
they were eligible to attend the most recent serological
surveillance round in 2006–2007 and if they had tested
HIV-positive in this, or any previous serological survey.
Data on HIV diagnoses covered the period 2005–2007, and
clinic data on ART screening covered the period from 2005
to 2009. For Masaka, the analysis was restricted to HIV-
infected participants who were resident at any point during
the 2005 or 2006 serological surveys and who were
diagnosed by December 2006. This restriction was made
because data on ART screening were only available up to
the end of 2008.
The distribution of the delay between diagnosis and
screening was compared across sites, by sex and age at
diagnosis. Chi-square tests were conducted to identify
socio-demographic characteristics associated with under-
going ART eligibility screening within 2 years of a HIV
diagnosis, with stratum-specific odds ratios examined to
check for possible interaction. Logistic regression was
used to build multivariable models for identifying the
socio-demographic factors that were independently asso-
ciated with ART screening within 2 years of a HIV
diagnosis.
Ethical approval
Each study site received ethical approval from a local
regulatory authority. The ALPHA network data sharing
agreement covered data sharing between sites.
Results
Characteristics of participants
The total number of HIV-infected adults in the analysis for
each site is shown in Table 2, by sex, age group and
education. Manicaland had the highest number of HIV-
infected individuals (n = 2057), while Masaka had the
fewest (n = 575), reflecting differences in study population
size and HIV prevalence. The sex and age distribution of
HIV-infected persons was similar across all settings,
although, in Karonga, they were slightly older than in the
other sites. The proportion of HIV-infected adults with
no schooling ranged from 3% in Karonga and Manicaland
to 30% in Kisesa.
HIV service coverage: a cross-sectional analysis
HIV service coverage among HIV-infected persons by the
selected survey round varied widely across sites (Table 3,
Figure 1). In Karonga, 95% of infected adults had learned
their HIV-positive status since the start of the national
ART programme, compared with 56% in Masaka, 37% in
Kisesa and 25% in Manicaland. The overall proportion of
HIV-infected persons on ART was highest in Masaka
(33%), followed by Karonga (23%) and was substantially
lower in Manicaland (2%) and Kisesa (1%).
Among the three sites with data on enrolment into ART
programmes, the proportion of HIV-diagnosed persons
Table 2 Socio-demographic characteristics of HIV-infected adults
in the cross-sectional analysis, by site
Site
Karonga
n (%)
Kisesa
n (%)
Masaka
n (%)
Manicaland
n (%)
All HIV-infected 837 (100) 686 (100) 575 (100) 2057 (100)
Sex
Men 308 (37) 250 (36) 214 (37) 639 (31)
Women 529 (63) 436 (64) 361 (63) 1418 (69)
Age
15–24 73 (9) 128 (19) 79 (14) 283 (14)
25–34 297 (35) 259 (38) 188 (33) 836 (41)
35–44 255 (30) 168 (24) 186 (32) 577 (28)
45+ 212 (25) 131 (19) 122 (21) 360 (18)
Education*
None 26 (3) 208 (30) 38 (7) 66 (3)
Primary 1–4 55 (7) 83 (12) 97 (17) 137 (7)
Primary 5–7 457 (55) 351 (51) 244 (42) 611 (30)
Secondary
or more
269 (32) 34 (5) 132 (23) 1236 (60)
*4% missing data in Karonga and 11% missing data in Masaka.
8 years of primary school education in Malawi.
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who had been screened for ART eligibility varied consid-
erably between sites, being highest in Masaka (255 ⁄322;
79%) and lowest in Kisesa (10 ⁄251; 4%). More than 90%
of those ever eligible to initiate ART had started treatment
in all three sites.
Within each site, there was little difference in the
proportions of men and women who had been diagnosed
with HIV or initiated ART, with the exception of
Manicaland where HIV testing uptake was lower among
men (Figure 1). The proportions diagnosed with HIV, and
on ART varied by age at diagnosis in all sites, with those in
the younger age groups being the least likely to know their
positive HIV status and those in the older age groups
being most likely to have initiated ART (Figure 1).
Antiretroviral therapy coverage among those estimated
to need treatment at the selected survey rounds ranged
from 2% in Kisesa to 68% in Masaka (Table 4). In
all sites, estimated ART coverage was higher among
women than men and was generally lowest among
15- to 24-year-olds. Estimated ART coverage was lower
among those with least education in all sites, except
Masaka.
Table 3 HIV service coverage among HIV-
infected persons by site: a cross-sectional
analysis
HIV service access
Site
Karonga
n (%)
Kisesa
n (%)
Masaka
n (%)
Manicaland
n (%)
All HIV-infected 837 (100) 676 (100) 575 (100) 2057 (100)
Knows status 788 (94) 251 (37) 322 (56) 524 (25)
Referred NA 84 (12) NA NA
Registered at HIV clinic NA 10 (1) NA NA
Completed ART screening 209 (25) 10 (1) 255 (44) NA
Ever eligible for ART* 202 (24) 6 (1) 191 (33) NA
Currently on ART 194 (23) 5 (1) 189 (33) 40 (2)
ART, antiretroviral therapy.
*According to screening results.
According to self-report for Manicaland, clinic data only for Kisesa & masaka and
combined self-report and clinic data for Karonga.
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Table 4 Antiretroviral therapy (ART) coverage
Site Variable Category HIV-positive
Estimated
ART need On ART*
Estimated
coverage
Karonga Total 837 334 194 (58)
Sex Male 308 130 62 (48)
Female 529 204 132 (65)
Age at serosurvey 15–24 73 12 3 (25)
25–34 297 74 60 (81)
35–44 255 81 65 (80)
45+ 212 84 66 (79)
Education level None 26 13 6 (46)
Primary 1–4 55 24 10 (41)
Primary 5–7 457 185 113 (61)
Secondary + 269 101 60 (59)
Kisesa Total 676 212 5 (2)
Sex Male 247 82 0 (–)
Female 429 131 5 (4)
Age at serosurvey 15–24 127 18 1 (6)
25–34 254 51 2 (4)
35–44 165 41 1 (2)
45+ 130 29 1 (3)
Education level None 208 72 1 (1)
Primary 1–4 83 27 1 (4)
Primary 5–7 351 105 2 (2)
Secondary + 34 9 1 (11)
Masaka Total 575 279 189 (68)
Sex Male 214 111 70 (63)
Female 361 168 119 (71)
Age at serosurvey 15–24 79 20 11 (54)
25–34 188 81 47 (58)
35–44 186 100 84 (84)
45+ 122 79 47 (60)
Education level None 38 21 14 (67)
Primary 1–4 97 50 38 (76)
Primary 5–7 244 116 73 (63)
Secondary + 132 63 42 (66)
Manicaland Total 2057 520 40 (8)
Sex Male 639 164 1 (1)
Female 1418 356 39 (11)
Age at serosurvey 15–24 283 38 2 (5)
25–34 836 186 8 (4)
35–44 577 169 15 (9)
45+ 360 128 15 (12)
Education level None 66 21 0 (–)
Primary 1–4 137 42 4 (10)
Primary 5–7 611 169 18 (11)
Secondary + 1236 287 18 (6)
*Determined through self-report for Manicaland, clinic data for Masaka & Kisesa, and combined self-report and clinic data for Karonga.
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Delays between a HIV diagnosis and ART screening:
prospective analysis
The proportion of diagnosed persons who were screened
for ART eligibility within 2 years of their HIV diagnosis
was highest in Masaka (248 ⁄295; 84%) and lowest in
Kisesa (36 ⁄251; 14%). The time from diagnosis to
screening was also shortest in Masaka, with 95%
(236 ⁄248) of screened patients being seen within
12 months of diagnosis, compared with 86% (31 ⁄36) in
Kisesa and 77% (127 ⁄164) in Karonga.
In all sites, the delay between a HIV diagnosis and ART
screening tended to be slightly shorter among men than
women (Figure 2). In Kisesa and Karonga, delays in being
screened for ART following a HIV diagnosis tended to be
shorter with increasing age, with a similar pattern
observed in Masaka, except for the oldest age group
(Figure 2).
Table 5 shows the crude and adjusted odds ratios of
ART screening within 2 years of HIV diagnosis by site. In
Karonga and Kisesa, age at diagnosis was associated with
ART screening in the crude analysis, with evidence of
higher odds of screening with older age groups (OR for
trend = 1.78, P < 0.001 and OR for trend = 1.55,
P < 0.017, respectively; chi-squared test for trend). In
Karonga only, the odds of screening were lowest among
those with secondary education, although there was only
weak evidence of an overall association with education
(P = 0.10). In Masaka, no associations were observed
between the socio-demographic characteristics and ART
screening in the crude analysis.
There was no evidence of interaction between the socio-
demographic variables and screening in any site. In
Karonga, age at diagnosis remained the only factor
associated with screening after controlling for sex, resi-
dence and education. In Kisesa, there was borderline
evidence that those aged 45 years and over had 2.6 times
the adjusted odds of being screened as those aged 25–
34 years (P = 0.10). In Masaka, there was no evidence of
an association with screening uptake for age, education or
sex in the adjusted model.
Discussion
Overall, this study shows substantial variation in HIV
service coverage in the four sites. In particular, among
adults who had tested HIV-positive in a serological survey,
the proportion who knew their status ranged from 25% in
Manicaland to 95% in Karonga, indicating that home-
based VCT services, such as the one accompanying the
HIV surveillance activities in Karonga, are a more effective
way of achieving universal diagnosis than are more
traditional VCT clinics, such as those provided during
survey rounds in Manicaland and Kisesa. While differences
in survey dates and population characteristics including
HIV prevalence will also partially explain the differences in
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testing uptake, they nevertheless add weight to arguments
that door-to-door testing may be the best way to achieve
higher rates of HIV diagnoses, although these services are
likely to be relatively expensive.
Nevertheless, this study also showed that higher diagnosis
rates do not necessarily translate into better ART coverage,
even when HIV clinics are locally available. The highest
level of estimated ART coverage was observed in Masaka,
despite having a lower proportion of HIV-infected persons
who knew their status (56%) than in Karonga (95%). In
addition, the probability of ART screening within 2 years of
a diagnosis was substantially higher in Masaka (84%) than
in Karonga (38%), suggesting that clients who have to
actively seek out their test results may be more motivated, or
Table 5 Factors associated with antiretroviral therapy (ART) screening within 2 years of a HIV diagnosis
Site Variable Category
Had VCT
N
Screened
for ART*
n (%)
Crude
odds
ratio 95% CI
Adjusted
odds ratio 95% CI
Karonga Total 432 162 (38)
Sex Male 170 69 (41) 1.24 (0.83–1.85) 1.03 (0.67–1.60)
Female 262 93 (35) 1.00 1.00
Age at diagnosis 15–24 40 6 (15) 0.44 (0.17–1.14) 0.46 (0.18–1.18)
25–34 169 48 (28) 1.00 1.00
35–44 128 56 (44) 1.96 (0.20–3.20) 1.86 (1.13–3.05)
45+ 95 52 (55) 3.04 (1.77–5.25) 3.09 (1.76–5.42)
Education* None ⁄ Primary 1–4 45 15 (33) 0.70 (0.36–1.37) 0.52 (0.25–1.05)
Primary 5–8 237 99 (42) 1.00 1.00
Secondary+ 136 42 (31) 0.79 (0.40–0.98) 0.70 (0.44–1.13)
Residence Rural 240 89 (37) 1.00 1.00
Roadside 192 73 (38) 1.04 (0.70–1.54) 0.93 (0.61–1.42)
Kisesa Total 251 36 (14)
Sex Male 98 14 (14) 0.99 (0.48–2.05) 0.85 (0.32–2.22)
Female 153 22 (14) 1.00 1.00
Age at diagnosis 15–24 41 5 (12) 1.18 (0.38–3.72) 1.02 (0.29–3.58)
25–34 95 10 (11) 1.00 1.00
35–44 69 7 (10) 0.96 (0.35–2.67) 0.59 (0.17–2.07)
45+ 46 14 (30) 3.72 (1.45–9.52) 2.57 (0.83–7.95)
Education* None 59 10 (17) 1.25 (0.55–2.84) 0.99 (0.36–2.72)
Primary 1–4 35 4 (11) 0.79 (0.25–2.47) 0.40 (0.08–1.93)
Primary 5–7 or more 157 22 (14) 1.00 1.00
Residence Rural 92 7 (8) 1.00 1.00
Roadside 70 10 (14) 2.02 (0.72–5.67) 1.78 (0.63–5.08)
Trading centre 77 8 (10) 1.41 (0.48–4.09) 1.34 (0.43–4.10)
Masaka Total 295 248 (84)
Sex Male 117 97 (83) 0.87 (0.46–1.63) 0.79 (0.40–1.57)
Female 178 151 (85) 1.00 1.00
Age at survey 15–24 30 23 (77) 0.63 (0.23–1.72) 0.60 (0.19–1.94)
25–34 105 88 (84) 1.00 1.00
35–44 106 91 (86) 1.17 (0.55–2.50) 1.21 (0.55–2.64)
45+ 54 46 (85) 1.11 (0.44–2.78) 1.22 (0.47–3.20)
Education* None 34 27 (79) 0.92 (0.35–2.40) 0.86 (0.32–2.29)
Primary 1–4 61 52 (85) 1.38 (0.59–3.23) 1.42 (0.60–3.38)
Primary 5–7 114 92 (81) 1.00 1.00
Secondary + 54 48 (89) 1.91 (0.72–5.08) 1.97 (0.73–5.31)
VCT, voluntary counselling and testing.
*Self-reported for Manicaland, clinic data for Kisesa & Masaka, and combined self-report and clinic data for Karonga.
Adjusted for all variables.
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able, to access HIV care. Furthermore, door-to-door testing
services that increase the proportion of individuals who are
aware of their status need to be balanced by efforts to
promote subsequent access to HIV clinics for monitoring
and timely treatment initiation, including effective referral
systems that include transportation allowances and addi-
tional supportive counselling (Nsigaye et al. 2009).
Estimated ART coverage was consistently lower among
men than women in all sites and tended to be lower among
those with least education and those in the youngest age
groups (with the exception of Kisesa, where numbers are
small). These emerging inequities suggest greater efforts
including community mobilisation, tailored health infor-
mation and youth-friendly initiatives are needed to attract
these under-served groups so that they can equally benefit
from these life-extending drugs. The particularly low
estimated ART coverage in Zimbabwe and Tanzania is
worrying, partly reflecting the later introduction of free
treatment programmes and decentralisation to rural areas,
but also being a function of the shorter interval between
ART introduction and the selected survey round, compared
with Karonga and Masaka.
There are several limitations to the analysis. Firstly, each
site used different methods to ascertain the number of
persons who had reached different stages of accessing
ART, which may partially account for the differences
observed. In Karonga, Kisesa and Masaka, VCT and ART
clinic data were linked to cohort data to obtain utilisation
rates, with additional reported information on VCT use
available from survey questionnaires and on ART initiation
for Karonga. In Karonga and Masaka where ART is
provided through a research clinic, the linkage procedures
use unique identifiers and are likely to effectively capture
around 90% of individuals accessing these services. In
Kisesa, underestimation of HIV service use is slightly more
likely because individuals accessing VCT services outside
of the sero-survey were linked to the dataset by counsellors
using name, residence, age and sex information, with
subsequent referral and ART clinic data linked in using
facility-allocated unique identifiers (Nsigaye et al. 2009).
In Manicaland, VCT and ART use were determined by
questionnaire alone, and so underestimation of coverage is
also possible, because of a greater opportunity for social
desirability bias.
Despite these limitations, this analysis is the first to
provide a detailed insight into the degree of access to ART
among all HIV-infected persons as well as among those
estimated to need treatment, by socio-demographic char-
acteristics in different settings, thus highlighting emerging
inequalities in treatment access. Furthermore, these results
provide an important baseline for future analyses that
monitor trends in HIV service coverage in these settings
and provide some evidence of the advantages and disad-
vantages of different HIV testing and ART provision
models that have been debated in recent years in terms of
promoting access to ART.
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